Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib plus Sintilimab as First-Line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma
ChiCTR2500107728Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vorolanib and sintilimab in non-clear cell renal cell carcinoma (nccRCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-Free Survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
vorolanibsintilimab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on ChiCTR2500107728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107728.